3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
2
Status
Completed
5
Terminated
4
Active not recruiting
4
Recruiting
1
Sponsor Class
INDUSTRY
4
OTHER
3
NIH
1
Study Type
Interventional
4
Sponsor
Cancer Type
Gynecologic
2
Thoracic
1
Gastrointestinal
1
Conditions
Ovarian Neoplasms
2
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
184
Carboplatin
132
Paclitaxel
101
Cisplatin
101
Gemcitabine
86
Pemetrexed
79
durvalumab
75
Nivolumab
66
Docetaxel
56
atezolizumab
52
Bevacizumab
50
Cyclophosphamide
49
Dexamethasone
45
Capecitabine
45
Oxaliplatin
43
130-nm albumin-bound paclitaxel
41
Rituximab
40
Fulvestrant
39
Lenalidomide
38
Fluorouracil
38
Prednisone
32
osimertinib
31
olaparib
29
Leucovorin
29
venetoclax
28
fludarabine
28
Trastuzumab
27
Doxorubicin
27
Etoposide
25
Cetuximab
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Active not recruiting
×
INDUSTRY
×
defactinib
×
Clear all
NCT05074810
2026-01-12
RAMP203
Verastem, Inc.
Phase 1/2
Active not recruiting
153 enrolled
NCT06682572
2025-12-17
RAMP201J
Verastem, Inc.
Phase 2
Active not recruiting
16 enrolled
NCT05669482
2025-09-02
RAMP205
Verastem, Inc.
Phase 1/2
Active not recruiting
40 enrolled
NCT04625270
2025-01-29
RAMP 201
Verastem, Inc.
Phase 2
Active not recruiting
225 enrolled
1 FDA